Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-12590154-B2 · Mar 31, 2026 · US
This page is not indexed by search engines while we improve data quality.
Cogswell John P patents
Cogswell John P is listed as an inventor on 41 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Cogswell John P |
| Total patents | 41 |
| First publication | May 7, 2015 |
| Latest publication | Mar 31, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2025270322-A1 · Aug 28, 2025 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2025263486-A1 · Aug 21, 2025 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2025257136-A1 · Aug 14, 2025 · US
Treatment of lag-3 positive tumors
US-2025043006-A1 · Feb 6, 2025 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2024417471-A1 · Dec 19, 2024 · US
Treatment of LAG-3 positive tumors
US-12049503-B2 · Jul 30, 2024 · US
Treatment of lag-3 positive tumors
US-2024092911-A1 · Mar 21, 2024 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2024034793-A1 · Feb 1, 2024 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2024002512-A1 · Jan 4, 2024 · US
Recent patents
Latest publications not already listed above.
Treatment of LAG-3 positive tumors
US-11807686-B2 · Nov 7, 2023 · US
Treatment of lag-3 positive tumors
US-2021261666-A1 · Aug 26, 2021 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2020308282-A1 · Oct 1, 2020 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10604575-B2 · Mar 31, 2020 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10584170-B2 · Mar 10, 2020 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10577423-B2 · Mar 3, 2020 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10323093-B2 · Jun 18, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10323092-B2 · Jun 18, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10316090-B2 · Jun 11, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10316091-B2 · Jun 11, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10308714-B2 · Jun 4, 2019 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2019153099-A1 · May 23, 2019 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2019135920-A1 · May 9, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10266594-B1 · Apr 23, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10266596-B1 · Apr 23, 2019 · US
Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US-10266595-B2 · Apr 23, 2019 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2019112377-A1 · Apr 18, 2019 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2019112376-A1 · Apr 18, 2019 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2019100589-A1 · Apr 4, 2019 · US
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US-2019100590-A1 · Apr 4, 2019 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Bristol Myers Squibb Co | 42 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61P35/00 | 41 |
| C07K16/2818 | 41 |
| C07K2317/76 | 41 |
| G01N2800/52 | 41 |
| A61K2039/505 | 41 |